Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

At least 30% of patients with rheumatoid arthritis (RA) do not respond to biologic agents, which emphasizes the need of predictive biomarkers. We aimed to identify microRNAs (miRNAs) predictive of response to adalimumab in 180 treatment-naïve RA patients enrolled in the OPtimized treatment algorithm...

Full description

Saved in:
Bibliographic Details
Published in:The pharmacogenomics journal 2016-04, Vol.16 (2), p.141-146
Main Authors: Krintel, S B, Dehlendorff, C, Hetland, M L, Hørslev-Petersen, K, Andersen, K K, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H M, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Horn, H C, Jørgensen, A, Raun, J, Ammitzbøll, C G, Østergaard, M, Stengaard-Pedersen, K, Johansen, J S
Format: Article
Language:English
Subjects:
45/77
692/53/2423
Adalimumab
Adalimumab - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - genetics
Biomarkers
Biomedical and Life Sciences
Biomedicine
Double-Blind Method
Double-blind studies
Drug metabolism
Drug therapy
Female
Gene Expression
Genetic aspects
Human Genetics
Humans
Male
Methotrexate
MicroRNAs
MicroRNAs - blood
Middle Aged
miRNA
Monoclonal antibodies
Oncology
original-article
Patient outcomes
Patients
Pharmacotherapy
Placebos
Prospective Studies
Psychopharmacology
Rheumatoid arthritis
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At least 30% of patients with rheumatoid arthritis (RA) do not respond to biologic agents, which emphasizes the need of predictive biomarkers. We aimed to identify microRNAs (miRNAs) predictive of response to adalimumab in 180 treatment-naïve RA patients enrolled in the OPtimized treatment algorithm for patients with early RA (OPERA) Study, an investigator-initiated, prospective, double-blind placebo-controlled study. Patients were randomized to adalimumab 40 mg ( n =89) or placebo–adalimumab ( n =91) subcutaneously in combination with methotrexate. Expressions of 377 miRNAs were determined using TaqMan Human MicroRNA LDA, A Card v2.0 (Applied Biosystems). Associations between miRNAs and treatment response were tested using interaction analyses. MiRNAs with a P -value
ISSN:1470-269X
1473-1150
DOI:10.1038/tpj.2015.30